- Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Demeter, L.M., Shafer, R.W., Meehan, P.M., Holden-Wiltse, J., Fischl, M.A., Freimuth, W.W., Para, M.F., Reichman, R.C. Antimicrob. Agents Chemother. (2000)